David A. Santos - 17 Feb 2026 Form 4 Insider Report for RIGEL PHARMACEUTICALS INC (RIGL)

Role
EVP, Chief Commercial Officer
Signature
/s/ Raymond Furey (Attorney-in-Fact)
Issuer symbol
RIGL
Transactions as of
17 Feb 2026
Net transactions value
$0
Form type
4
Filing time
19 Feb 2026, 17:06:06 UTC
Previous filing
12 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Santos David A EVP, Chief Commercial Officer RIGEL PHARMACEUTICALS, INC., 611 GATEWAY BLVD, SUITE 900, SOUTH SAN FRANCISCO /s/ Raymond Furey (Attorney-in-Fact) 19 Feb 2026 0001820066

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RIGL Common Stock Award $0 +19,430 +45% $0.000000 62,870 17 Feb 2026 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares of common stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall vest quarterly over three (3) years, with the first quarterly vest occurring on March 31, 2026.